| Status: | Phase 3 |
| Entry Type: | Antibody |
| UNII: | 13ZEQ1M5ML |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Scleroderma, Systemic | 3 | D012595 | ClinicalTrials |
| Neuromyelitis Optica | 3 | D009471 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL5314981 |
| FDA SRS | 13ZEQ1M5ML |
CONTENTS